Autonomix Medical, Inc. (AMIX) Form 424B5 — Sep 11, 2026
Autonomix Medical filed a prospectus supplement establishing capacity to sell up to $10.525 million of common stock through an at-the-market offering with Ladenburg Thalmann, which earns a 3.0% commission on gross proceeds. Proceeds are earmarked for working capital and general corporate purposes. At the September 8, 2026 closing price of $4.58, full use of the ATM would issue roughly 2,298,035 new shares on top of 1,959,938 currently outstanding, more than doubling the share count — although actual sales are at management's discretion and there is no assurance any shares will be sold.
Key figures
- Gross Proceeds
- up to $10,525,000
- Offering Price
- at-the-market; $4.58 reference close on Sep 8, 2026
- Shares Offered
- up to 2,298,035 (at assumed $4.58)
- Shares Outstanding
- 1959938
- Public float value
- $35,327,292 (based on Aug 4, 2026 price)
- Nasdaq mvls threshold
- $5.0 million
- Sales agent commission
- 3.0% of gross proceeds
- Authorized common shares
- 500000000
- Potential dilution percent
- ~117%
- Prior 12m baby shelf sales
- $1,227,732
- Estimated offering expenses
- $50,000
- Agent counsel reimbursement cap
- $50,000
- Post offering shares outstanding
- up to 4,257,973
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.